F11 coagulation factor XI
ENSG00000088926 · protein coding · Open Targets profile
Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Advanced Clinical, Structure with Ligand, High-Quality Ligand, Med-Quality Pocket, Druggable Family
- Antibody
- Advanced Clinical, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 1.0196000337600708 (upper bound 1.2309000492095947). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 38 registry trials, updated in the last three years, of the most advanced drugs against F11 (human c1-esterase inhibitor, abelacimab, osocimab, milvexian), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Anurag RelanPharming Technologies BV · 2 of 2 trials Phase 2+
- Jonathan BernsteinBernstein Clinical Research Center · 2 of 2 trials Phase 2+
- Diethard MonbaliuAbdominal transplant surgery - transplant coordination, Abdominal transplant surgery lab (microbiology & immunology Dpt) · 1 of 1 trials Phase 2+
- Emel Aygören-PürsünUniversity Hospital Frankfurt - Goethe University, Frankfurt, Germany · 1 of 1 trials Phase 2+
- Marc RiedlUC San Diego, La Jolla, California, United States · 1 of 1 trials Phase 2+
- Marcus MaurerCharite University, Berlin, Germany · 1 of 1 trials Phase 2+
- Michael OsthoffUniversity Hospital Basel, Division of Internal Medicine · 1 of 1 trials Phase 2+
- Murat BasKlinikum rechts der Isar · 1 of 1 trials Phase 2+
- Peter S HeegerCedars-Sinai Medical Center · 1 of 1 trials Phase 2+
- Raban JegerStadtspital Triemli Zürich, Division of Cardiology · 1 of 1 trials Phase 2+
- Sindhu ChandranCedars-Sinai Medical Center · 1 of 1 trials Phase 2+
- Stanley JordanCedars-Sinai Medical Center · 1 of 1 trials Phase 2+
- Wouter MoojenHaaglanden Medisch Centrum · 1 of 1 trials Phase 2+
- Marie-Thérèse RUBIOSaint Antoine Hospital · 0 of 1 trials Phase 2+
Registry trials of human c1-esterase inhibitor, abelacimab, osocimab, milvexian updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 21 of 37 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
13 trials of drugs against F11 were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of human c1-esterase inhibitor, abelacimab, osocimab, milvexian, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 13 most recent of 13.
- terminated · 2026-08-17 · Pharvaris Netherlands B.V. · matched by the registry's drug synonyms“Sponsor decision. All remaining participants (21 total) were rolled over from Part 2 to study PHA022121-C307 (NCT06679881).”
- terminated · 2026-04-17 · Anthos Therapeutics, Inc. · Abelacimab“Sponsor Decision”
- terminated · 2026-02-23 · Anthos Therapeutics, Inc. · Abelacimab“Sponsor decision”
- terminated · 2024-04-03 · Pharming Technologies B.V. · matched by the registry's drug synonyms“Lower than expected study enrolment rate. New strategic considerations.”
- terminated · 2022-07-29 · CSL Behring · matched by the registry's drug synonyms“The study was terminated early due to futility of enrolment and not for safety reasons.”
- withdrawn · 2022-02-04 · AO GENERIUM · matched by the registry's drug synonyms“Company pipeline revision”
- terminated · 2021-11-09 · University Hospital, Basel, Switzerland · matched by the registry's drug synonyms“Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.”
- terminated · 2021-01-19 · TSI, LLC · matched by the registry's drug synonymsNo reason given
- terminated · 2020-07-13 · Shire · matched by the registry's drug synonyms“Following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility.”
- terminated · 2020-06-24 · T. van der Poll · matched by the registry's drug synonyms“Interim analysis showed no differences between groups”
- terminated · 2015-02-04 · UMC Utrecht · matched by the registry's drug synonyms“Futility and limited feasibility”
- withdrawn · 2012-11-30 · Penn State University · matched by the registry's drug synonyms“PennState would not allow the study to move forward”
- withdrawn · 2012-02-17 · Pharming Technologies B.V. · matched by the registry's drug synonyms“Recent improvements in clinical practice have reduced the apparent incidence of AMR in renal transplantation.”
Paediatric incentives and obligations for F11's drugs
For human c1-esterase inhibitor, abelacimab, osocimab, milvexian: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · F11 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000226657 (abelacimab, Prevention of thromboembolic events;Treatment of thromboembolic events): PM: decision on the application for modification of an agreed PIP, 28 Jan 2025; EMEA-003220-PIP01-22-M01 (milvexian, Prevention of thromboembolism in patients with cardiovascular diseases): PM: decision on the application for modification of an agreed PIP, 12 Apr 2024Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names human c1-esterase inhibitor, abelacimab, osocimab, milvexianRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of human c1-esterase inhibitor, abelacimab, osocimab, milvexianRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of human c1-esterase inhibitor, abelacimab, osocimab, milvexianRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 30 interventional studies of human c1-esterase inhibitor, abelacimab, osocimab, milvexian include patients under 18; 2 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 4 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| HUMAN C1-ESTERASE INHIBITOR | Protein | approval | hereditary angioedema, angioedema | Open Targets · ChEMBL |
| ABELACIMAB | Antibody | phase 3 | venous thromboembolism, hemorrhage, atrial fibrillation | Open Targets · ChEMBL |
| OSOCIMAB | Antibody | phase 2 | thrombotic disease | Open Targets · ChEMBL |
| MILVEXIAN | Small molecule | phase 2 | ischemic stroke, brain ischemia, cerebral infarction, chronic kidney disease, stage 5 chronic kidney disease, thrombotic disease | Open Targets · ChEMBL |